1 / 42

Evaluating COPD Services

Evaluating COPD Services. Insights from Economics Dr. Andrew Walker. Structure. How are we taking account of costs just now? Assessment of new medicines at national level Case studies of economic evaluation of pulmonary rehabilitation Using economic evaluation locally. The state we’re in ….

denzel
Télécharger la présentation

Evaluating COPD Services

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Evaluating COPD Services Insights from Economics Dr. Andrew Walker

  2. Structure • How are we taking account of costs just now? • Assessment of new medicines at national level • Case studies of economic evaluation of pulmonary rehabilitation • Using economic evaluation locally

  3. The state we’re in …

  4. Health Committee Report • Financial state of NHS, May 2010 • Spending growing by 4-5% per annum • Funding for NHS boards grew by 2% this year • Gap covered by “efficiency savings” • Creates problem for investment that will not go away for several years

  5. For discussion: How do we take account of costs, affordability and value for money just now?

  6. Is anything getting funded? The case of new medicines

  7. Scottish Medicines Consortium • Since 2002 advised on all new medicines • Effectiveness, cost-effectiveness and other criteria (as appropriate) • Manufacturer assembles evidence base, which is critically appraised • Still subject to local formulary listing • www.scottishmedicines.org

  8. Declare my conflicts of interest!!!

  9. How does SMC do it? And what can we learn?

  10. SMC system • Submission from manufacturer • Appraised by pharmacist and economist • Access to clinician experts • Report on strengths and weaknesses of the case made • Consider written submission from patient interest group • Decision: accepted for use or not recommended

  11. Cost-effectiveness • Balance between added cost and added benefit (in terms of improved health) • Broad view of costs, long-term • Savings • Change in survival • Change in quality-of-life • Latter factors captured in the QALY

  12. COPD at SMC • Accepted for use: • Seretide, Symbicort, Spiriva • But we haven’t said which is best • Not recommended • Erdosteine, Seretide for moderate COPD • Next decision due in ten days: roflumilast

  13. Calculating an ICER

  14. New Medicine Randomised controlled trial design Adequate sample size so stats tests can be used Final/proxy outcomes Adequate follow-up (time) Service Development “Before and after” trial design Sample: whoever turns up Pre-existing data collection only Follow-up of a few weeks Contrast

  15. Useful Concepts? • Utilities • Costs of events • Speed of progression • Incremental analysis • Savings • Sensitivity analysis

  16. Question: where full health = 1 and “as bad as dead” = 0, where would you rate the average COPD patient?

  17. Examples of utilities Daily quality of life • Mild COPD 0.81 • Moderate COPD 0.72 • Severe COPD 0.67 Severe exacerbation • Halves the figures above, or • 0.52 (if mild COPD), 0.45 (if moderate COPD) or 0.41 (if severe COPD)

  18. Question: what do you think it costs the NHS per severe exacerbation?

  19. Costs • Gani et al – Delphi Panel of Scottish clinicians estimated resource use • Of pts suffering a severe exacerbation: • 65% require admission @ £3,564 each • 23% managed in community @ £566 each • 5% self-managed @ £0 (to NHS) • Average £2,516 • Duration of 1 month (NOT all in hospital)

  20. Question: how quickly does COPD progress e.g. from moderate to severe?

  21. Natural history • Economists construct models of the natural history of disease • Each year a patient with COPD that is • mild has 3% risk of developing moderate • moderate has 10% risk of severe COPD • Increasing risk of severe exacerbation (5% in mild, 8.5% moderate, 15% severe) • 11-15% chance of mortality

  22. Thinking • Need to compare to what we do now, what does new treatment ADD? • What are we trying to achieve: • Patient satisfaction • Clinical outcome • Patient outcome

  23. Savings • NHS costs = staff + buildings & equipment + medicines • When we avoid an exacerbation do we need: • Less staff? • Less buildings? • Less medicines? • Freeing up time, not making cash savings

  24. Sensitivity analysis • Lack of evidence is a barrier to evaluation e.g. before-and-after design • Sensitivity analysis explores uncertainty • “What if…?” • Effectiveness is only half efficacy • Hospital length-of-stay fell anyway • There is a longer-term mortality benefit • In terms of impact on costs and benefits

  25. What do we know about cost-effectiveness beyond new medicines?

  26. “The literature” • Cost per QALY studies in COPD: • Lots on smoking cessation • Lots on prescribing • Two evaluations of pulmonary rehabilitation • What do they show and can we rely on it?

  27. Case Study 1 – Griffiths et al

  28. Additional data (Lanect)

  29. Case Study 2 – Hoogendoorn et al

  30. Some issues • Definition of rehab and ‘usual care’ • Timescale and perspective (breadth) • Shelf-life, when practice is changing • Efficacy trial vs day-to-day practice • Different result in less severe disease? • Nature of savings – cash versus time • Does the NHS understand QALYs? • What is “good value”?

  31. Savings on hospital time • 400 bed-days in a year • 24-bed ward has 8742 potential bed-days • 80% occupancy means 6994 used • Reduced by 400, brings occupancy down to 75% occupancy • Roughly equivalent to 1.5 beds (1.5*365*0.8 = 438)

  32. Can you use these studies to make a case for funding locally?

  33. Nationally QIS standard SMC SIGN Targets (HEAT) May or may not include economic evaluation already Locally Things that that have not been evaluated nationally Policy or target set nationally, local challenge is how to achieve the goal Savings required Types of decision

  34. National evaluation Examples • New medicines through SMC • Case-finding: screening smokers for COPD • DOTS through Scottish Government initiative • Pulmonary rehabilitation – established in QIS standard

  35. What are the options for doing a local evaluation?

  36. Cost-minimisation analysis • Use when: you expect outcomes to be the same • Choose the cheapest • But how will you define costs • NHS or beyond? • Financial or economic? • And do you know outcomes are the same?

  37. Cost-effectiveness analysis • Use: when there are different ways of achieving an objective • E.g. admissions avoided • Compare options in terms of added cost per admission avoided • But how will you know admissions are avoided? • And what are we willing to pay?

  38. Cost-consequence analysis • Use: when service has multiple benefits, some not easily measured • Evaluation is in terms of costs versus benefits as “bullet point list” • But how do you come to a decision? • And, again, how do you know what the benefits are?

  39. Costs Added staff costs Higher paid Slower Prescribe more Less overheads Overall £100 more per patient per yera Consequences Shorter waiting time by 6 weeks Greater patient satisfaction (85% versus 70%) Slightly better outcomes (5% better FEV1) Hypothetical GPwSI

  40. Programme budgeting • Use: when reviewing the whole service in an area e.g. COPD in a CHP • Establish total spend • Could it be spent to better effect, to get more total benefit? • Raises questions, options for change • Apply evaluation techniques to the options

More Related